OR03-1 Achievement of HbA1c <6.5% without weight gain and hypoglycemia in people with type 2 diabetes treated with tirzepatide across the phase 3 SURPASS program

por Allen, Sheryl Elaine, Cheng, Alice, Choudhary, Pratik, Levine, Joshua A, Ranta, Kari, Thieu, Vivian Thuyanh, Valderas, Elisa Gomez, Lingvay, Ildiko
Publicado 2022

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

por Schnell, Oliver, Battelino, Tadej, Bergenstal, Richard, Birkenfeld, Andreas L., Ceriello, Antonio, Cheng, Alice, Davies, Melanie, Edelman, Steve, Forst, Thomas, Giorgino, Francesco, Green, Jennifer, Groop, Per-Henrik, Hadjadj, Samy, J.L.Heerspink, Hiddo, Hompesch, Marcus, Izthak, Baruch, Ji, Linong, Kanumilli, Naresh, Mankovsky, Boris, Mathieu, Chantal, Miszon, Martin, Mustafa, Reem, Nauck, Michael, Pecoits-Filho, Roberto, Pettus, Jeremy, Ranta, Kari, Rodbard, Helena W., Rossing, Peter, Ryden, Lars, Schumm-Draeger, Petra-Maria, Solomon, Scott D., Škrha, Jan, Topsever, Pinar, Vilsbøll, Tina, Wilding, John, Standl, Eberhard
Publicado 2023